Brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings per share of $16.70 for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $21.71 and the lowest is $7.64. Regeneron Pharmaceuticals reported earnings of $9.53 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 75.2%. The business is expected to report its next quarterly earnings results on Friday, February 4th.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $67.30 per share for the current year, with EPS estimates ranging from $43.09 to $73.70. For the next fiscal year, analysts expect that the firm will report earnings of $46.98 per share, with EPS estimates ranging from $35.38 to $65.41. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $9.81 by $5.56. The firm had revenue of $3.45 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 50.38% and a net margin of 51.65%. The company’s quarterly revenue was up 50.5% compared to the same quarter last year. During the same period in the previous year, the business posted $7.68 EPS.
In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $576.75, for a total transaction of $576,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George L. Sing sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $657.50, for a total value of $1,315,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,079 shares of company stock valued at $30,010,914. Insiders own 11.84% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Heritage Wealth Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $30,000. Gleason Group Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Arkadios Wealth Advisors raised its stake in Regeneron Pharmaceuticals by 96.6% in the 2nd quarter. Arkadios Wealth Advisors now owns 57 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Evoke Wealth LLC raised its stake in Regeneron Pharmaceuticals by 427.3% in the 3rd quarter. Evoke Wealth LLC now owns 58 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 47 shares during the period. Finally, Sandy Spring Bank raised its stake in Regeneron Pharmaceuticals by 416.7% in the 2nd quarter. Sandy Spring Bank now owns 62 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 50 shares during the period. Institutional investors own 82.08% of the company’s stock.
Shares of Regeneron Pharmaceuticals stock traded down $1.14 during trading on Thursday, hitting $648.18. 545,233 shares of the company were exchanged, compared to its average volume of 850,101. The firm has a market capitalization of $69.71 billion, a P/E ratio of 10.35, a price-to-earnings-growth ratio of 1.16 and a beta of 0.19. Regeneron Pharmaceuticals has a 1-year low of $441.00 and a 1-year high of $686.62. The firm’s fifty day moving average price is $606.80 and its 200 day moving average price is $588.14. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.71 and a quick ratio of 3.16.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Recommended Story: What is a CD ladder?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.